Litcius/Paper detail

The major histocompatibility complex participates in Parkinson’s disease

Rou Gu, Jianyu Pan, Maher Un Nisa Awan, Xiaowei Sun, Yan Fang, Liping Bai, Jie Bai

2024Pharmacological Research10 citationsDOIOpen Access PDF

Abstract

Parkinson’s disease (PD) is a common neurodegenerative disease characterized by progressive loss of dopaminergic neurons in the substantia nigra and the aggregation of alpha-synuclein (α-syn). The central nervous system (CNS) has previously been considered as an immune-privileged area. However, studies have shown that the immune responses are involved in PD. The major histocompatibility complex (MHC) presents antigens from Antigen-presenting cells(APCs) to T lymphocytes, immune responses will be induced. MHCs are expressed in microglia, astrocytes, and dopaminergic neurons. Single nucleotide polymorphisms in MHC are related to the risk of PD. The aggregated α-syn triggers the expression of MHCs by activating glia cells. CD4+ and CD8+ T lymphocytes responses and microglia activation are detected in brains of PD patients. In addiction immune responses further increase blood-brain barrier (BBB) permeability and T cell infiltration in PD. Thus, MHCs are involved in PD through participating in immune and inflammatory responses.

Topics & Concepts

Parkinson's diseaseMajor histocompatibility complexHistocompatibilityDiseaseMedicineImmunologyAntigenHuman leukocyte antigenPathologyParkinson's Disease Mechanisms and TreatmentsLysosomal Storage Disorders ResearchNeuroinflammation and Neurodegeneration Mechanisms
The major histocompatibility complex participates in Parkinson’s disease | Litcius